LAPTM4A and glioma: Our results revealed that the group with high expression of LAPTM4A had a tendency to have a high TIDE score, implying that overexpression of LAPTM4A may reduce the effectiveness of immunotherapy in glioma patients while lowering LAPTM4A expression may improve the response rate to immunotherapy in patients.